The Tubulin Colchicine Domain: a Molecular Modeling Perspective

Computational approaches have been increasingly applied to drug design over the past three decades and have already provided some useful results in the discovery of anticancer drugs. Given the increased availability of crystal structures in recent years, a growing number of molecular modeling studies on tubulin have been reported. Herein we present a brief overview of the role played by computational methods in anti‐tubulin research, specifically in the context of colchicine binding agent research. An overview of current structures is reported, along with a brief discussion on the issues associated with the various tubulin isotypes. Finally, a summary of the most recent and relevant results is presented, highlighting the challenges and opportunities faced by researchers in this field.

[1]  Carlos Alfonso,et al.  Stathmin and Interfacial Microtubule Inhibitors Recognize a Naturally Curved Conformation of Tubulin Dimers* , 2010, The Journal of Biological Chemistry.

[2]  G. Gordon,et al.  A Phase II Study of ABT-751 in Patients with Advanced Non-small Cell Lung Cancer , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  A. Yamaguchi,et al.  Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. , 1997, Cancer research.

[4]  E. Hamel,et al.  Separation of active tubulin and microtubule-associated proteins by ultracentrifugation and isolation of a component causing the formation of microtubule bundles. , 1984, Biochemistry.

[5]  H. Mohri Amino-acid Composition of “Tubulin” constituting Microtubules of Sperm Flagella , 1968, Nature.

[6]  Andrea Brancale,et al.  New arylthioindoles: potent inhibitors of tubulin polymerization. 2. Structure-activity relationships and molecular modeling studies. , 2006, Journal of medicinal chemistry.

[7]  P. Canonico,et al.  Solution-phase parallel synthesis and biological evaluation of combretatriazoles. , 2008, Journal of combinatorial chemistry.

[8]  T. Fojo,et al.  Tubulin/microtubules: still a promising target for new chemotherapeutic agents. , 2000, Journal of the National Cancer Institute.

[9]  A. Coluccia,et al.  Molecular modelling studies on Arylthioindoles as potent inhibitors of tubulin polymerization. , 2011, European journal of medicinal chemistry.

[10]  R. Luduena,et al.  Different Effects of Vinblastine on the Polymerization of Isotypically Purified Tubulins from Bovine Brain , 2003, Investigational New Drugs.

[11]  M. Carré,et al.  Interaction of 4-arylcoumarin analogues of combretastatins with microtubule network of HBL100 cells and binding to tubulin. , 2006, Biochemistry.

[12]  Patrick A. Curmi,et al.  Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain , 2004, Nature.

[13]  Hai‐Liang Zhu,et al.  Synthesis, biological evaluation, and molecular modeling of cinnamic acyl sulfonamide derivatives as novel antitubulin agents. , 2011, Bioorganic & medicinal chemistry.

[14]  M. De Brabander,et al.  The effects of methyl (5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl) carbamate, (R 17934; NSC 238159), a new synthetic antitumoral drug interfering with microtubules, on mammalian cells cultured in vitro. , 1976, Cancer research.

[15]  S. Monti,et al.  Novel imidazole-based combretastatin A-4 analogues: evaluation of their in vitro antitumor activity and molecular modeling study of their binding to the colchicine site of tubulin. , 2006, Bioorganic & medicinal chemistry letters.

[16]  F. Mollinedo,et al.  Isocombretastatins A: 1,1-diarylethenes as potent inhibitors of tubulin polymerization and cytotoxic compounds. , 2009, Bioorganic & medicinal chemistry.

[17]  C. Dumontet,et al.  Microtubule-binding agents: a dynamic field of cancer therapeutics , 2010, Nature Reviews Drug Discovery.

[18]  N. Lawrence,et al.  The chemistry and biology of antimitotic chalcones and related enone systems. , 2005, Current pharmaceutical design.

[19]  Kenneth H. Downing,et al.  Structure of the αβ tubulin dimer by electron crystallography , 1998, Nature.

[20]  D. Sackett Podophyllotoxin, steganacin and combretastatin: natural products that bind at the colchicine site of tubulin. , 1993, Pharmacology & therapeutics.

[21]  Jack A. Tuszynski,et al.  Free Energy Calculations on the Binding of Colchicine and Its Derivatives with the α/β-Tubulin Isoforms , 2008, J. Chem. Inf. Model..

[22]  D. Alberts,et al.  Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4 , 1989, Experientia.

[23]  T. Fojo,et al.  Epothilones: a novel class of non-taxane microtubule-stabilizing agents. , 2002, Current pharmaceutical design.

[24]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[25]  J. Snyder,et al.  Microtubule-interacting drugs for cancer treatment. , 2003, Trends in pharmacological sciences.

[26]  I. Barasoain,et al.  Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8-dihydropteridine antitumor drug, CI 980, and by its chiral isomer, NSC 613863. , 1994, Cancer research.

[27]  R. Ravelli,et al.  Microtubule-destabilizing agents: structural and mechanistic insights from the interaction of colchicine and vinblastine with tubulin. , 2009, Topics in current chemistry.

[28]  J. Tuszynski,et al.  Comparative modelling of human β tubulin isotypes and implications for drug binding , 2006, Nanotechnology.

[29]  L. Alphs JANSSEN , 2012, Schizophrenia Research.

[30]  J. Tuszynski,et al.  Homology modeling of tubulin: influence predictions for microtubule’s biophysical properties , 2006, European Biophysics Journal.

[31]  Andrew J. S. Knox,et al.  Integration of ligand and structure-based virtual screening for the identification of the first dual targeting agent for heat shock protein 90 (Hsp90) and tubulin. , 2009, Journal of medicinal chemistry.

[32]  Y. Engelborghs,et al.  Interactions of a bicyclic analog of colchicine with beta-tubulin isoforms alphabeta(II), alphabeta(III) and alphabeta(IV). , 1997, European journal of biochemistry.

[33]  Young Hoon Kim,et al.  Structure-based virtual screening of novel tubulin inhibitors and their characterization as anti-mitotic agents. , 2010, Bioorganic & medicinal chemistry.

[34]  Paraskevi Giannakakou,et al.  Targeting microtubules for cancer chemotherapy. , 2005, Current medicinal chemistry. Anti-cancer agents.

[35]  M. Jordan,et al.  Effects of vinblastine, podophyllotoxin and nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in mitosis. , 1992, Journal of cell science.

[36]  Timothy J Mitchison,et al.  Small molecules, big impact: a history of chemical inhibitors and the cytoskeleton. , 2002, Chemistry & biology.

[37]  J. Jaén,et al.  Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Tudor I. Oprea,et al.  Novel derivatives of 1,3,4-oxadiazoles are potent mitostatic agents featuring strong microtubule depolymerizing activity in the sea urchin embryo and cell culture assays. , 2010, European journal of medicinal chemistry.

[39]  Kui Cheng,et al.  Synthesis, molecular modeling and biological evaluation of dithiocarbamates as novel antitubulin agents. , 2010, Bioorganic & medicinal chemistry.

[40]  L. Kotra,et al.  Mechanism of action of N-phenyl-N'-(2-chloroethyl)ureas in the colchicine-binding site at the interface between alpha- and beta-tubulin. , 2009, Bioorganic & medicinal chemistry.

[41]  P. Price,et al.  Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  A. Brancale,et al.  Design, synthesis and structure-activity relationship of 2-(3',4',5'-trimethoxybenzoyl)-benzo[b]furan derivatives as a novel class of inhibitors of tubulin polymerization. , 2009, Bioorganic & medicinal chemistry.

[43]  D. Zisterer,et al.  Synthesis, evaluation and structural studies of antiproliferative tubulin-targeting azetidin-2-ones. , 2011, Bioorganic & medicinal chemistry.

[44]  E. Shooter,et al.  Structure of the tubulin dimer. , 1977, The Journal of biological chemistry.

[45]  G. G. Stokes "J." , 1890, The New Yale Book of Quotations.

[46]  R. Luduena,et al.  Kinetics of colchicine binding to purified β-tubulin isotypes from bovine brain , 1992 .

[47]  Z. Deng,et al.  Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions. , 2004, Journal of medicinal chemistry.

[48]  Richard A. Stanton,et al.  Drugs that target dynamic microtubules: A new molecular perspective , 2011, Medicinal research reviews.

[49]  M. Lind,et al.  Do β-tubulin mutations have a role in resistance to chemotherapy? , 2004 .

[50]  B. Hill,et al.  Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. , 2001, Critical reviews in oncology/hematology.

[51]  M. Steinmetz,et al.  Structural basis for the regulation of tubulin by vinblastine , 2005, Nature.

[52]  B. Bhattacharyya,et al.  Anti‐mitotic activity of colchicine and the structural basis for its interaction with tubulin , 2008, Medicinal research reviews.

[53]  N. Lawrence,et al.  Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle , 1998, Medicinal research reviews.

[54]  P. Curmi,et al.  The 4 Å X-Ray Structure of a Tubulin:Stathmin-like Domain Complex , 2000, Cell.

[55]  J. Bryan,et al.  Are cytoplasmic microtubules heteropolymers? , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[56]  T. Arai Inhibition of microtubule assembly in vitro by TN‐16, a synthetic antitumor drug , 1983, FEBS letters.

[57]  I. S. Johnson,et al.  THE VINCA ALKALOIDS: A NEW CLASS OF ONCOLYTIC AGENTS. , 1963, Cancer research.

[58]  R. Gambari,et al.  Synthesis and biological evaluation of 2-amino-3-(3',4',5'-trimethoxybenzoyl)-5-aryl thiophenes as a new class of potent antitubulin agents. , 2006, Journal of medicinal chemistry.

[59]  E. Taylor,et al.  The colchicine-binding protein of mammalian brain and its relation to microtubules. , 1968, Biochemistry.

[60]  Jonathan Y. Mane,et al.  Computer assisted design of second-generation colchicine derivatives , 2010, Interdisciplinary Sciences: Computational Life Sciences.

[61]  W. Figg,et al.  2‐Methoxyestradiol, a Promising Anticancer Agent , 2003, Pharmacotherapy.

[62]  Ki Young Lee,et al.  Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin. , 2006, Journal of medicinal chemistry.

[63]  M. Fornabaio,et al.  Docking and hydropathic scoring of polysubstituted pyrrole compounds with antitubulin activity. , 2008, Bioorganic & medicinal chemistry.

[64]  Jonathan Y. Mane,et al.  Quantitative analysis of the effect of tubulin isotype expression on sensitivity of cancer cell lines to a set of novel colchicine derivatives , 2010, Molecular Cancer.

[65]  D. Zaharevitz,et al.  A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach. , 2005, Journal of medicinal chemistry.

[66]  Raimond B G Ravelli,et al.  Variations in the colchicine-binding domain provide insight into the structural switch of tubulin , 2009, Proceedings of the National Academy of Sciences.

[67]  Ping-Chiang Lyu,et al.  Generation of ligand-based pharmacophore model and virtual screening for identification of novel tubulin inhibitors with potent anticancer activity. , 2009, Journal of medicinal chemistry.

[68]  Weijing Sun,et al.  Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  P. Vandenabeele,et al.  The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet , 2002, Cell Death and Differentiation.

[70]  J. Lewin,et al.  A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. , 2002, Cancer research.

[71]  L. Wilson,et al.  Mechanism of inhibition of microtubule polymerization by colchicine: inhibitory potencies of unliganded colchicine and tubulin-colchicine complexes. , 1992, Biochemistry.

[72]  P. Sylvester,et al.  Design and pharmacophore modeling of biaryl methyl eugenol analogs as breast cancer invasion inhibitors. , 2010, Bioorganic & Medicinal Chemistry.

[73]  Giovanni Sorba,et al.  Medicinal chemistry of combretastatin A4: present and future directions. , 2006, Journal of medicinal chemistry.

[74]  D. Covell,et al.  Mapping the binding site of colchicinoids on beta -tubulin. 2-Chloroacetyl-2-demethylthiocolchicine covalently reacts predominantly with cysteine 239 and secondarily with cysteine 354. , 2000, The Journal of biological chemistry.

[75]  P. Fu,et al.  A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. , 2009, Thyroid : official journal of the American Thyroid Association.

[76]  Raimond B G Ravelli,et al.  Structural insight into the inhibition of tubulin by vinca domain peptide ligands , 2008, EMBO reports.

[77]  Liying Zhang,et al.  Antitumor agents. 284. New desmosdumotin B analogues with bicyclic B-ring as cytotoxic and antitubulin agents. , 2011, Journal of medicinal chemistry.

[78]  B. Potter,et al.  Class III β-tubulin expression and in vitro resistance to microtubule targeting agents , 2009, British Journal of Cancer.

[79]  F. Cabral,et al.  Molecular Basis for Class V β-Tubulin Effects on Microtubule Assembly and Paclitaxel Resistance* , 2009, Journal of Biological Chemistry.

[80]  F. Giles,et al.  Microtubule dynamics as a target in oncology. , 2009, Cancer treatment reviews.

[81]  R. Donehower,et al.  Drug therapy : paclitaxel (Taxol) , 1995 .